ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
EndoGastric Solutions(TM) Announces Results Of EsophyX(TM) Multi-Center GERD Study
EndoGastric Solutions, the
world leader in natural orifice surgery products and
procedures, announces outstanding results at the completion
of 1-year follow-up on GERD patients in the phase 2
multi-center study of the first generation transoral
incisionless fundoplication (TIF 1) procedure and
first-generation EsophyX device. EndoGastric Solutions is
the first company to successfully design truly incisionless
transoral surgical products that mimic the outcomes of the
more invasive gold-standard antireflux surgeries,
laparoscopic fundoplications (i.e. Nissen, Toupet or Hill
procedures). The EsophyX device enables surgeons and
advanced interventional gastroenterologists to offer their
patients substantive anatomical repair without incisions (no
skin or internal dissection) for front-line surgical
management of gastroesophageal reflux disease (GERD)
patients.
Dr. John Hunter, Professor and Chairman of the Department of
Surgery at Oregon Health & Science University in Portland,
Oregon, states, "For years, the medical community has been
looking for less invasive ways to treat GERD patients to
reduce their dependence on pharmaceuticals. Our department
has studied the effects of these pharmaceuticals and is
concerned that there are additional detrimental effects that
should be avoided. EsophyX is an impressive technology with
impressive results that advances the treatment of GERD a
giant leap forward."
Dr. Todd Overcash, Medical Director of Bariatric and
Minimally Invasive Surgery at Munroe Regional Medical Center
in Ocala, Florida, is the United States leader of NOS
(Natural Orifice Surgery) procedures performed. He was among
the first U.S. surgical teams that went to Europe last fall
to train on this new technique. He has now performed more
EsophyX procedures than any surgeon in the U.S. and states:
"Having performed 38 advanced TIF procedures with the
EsophyX device in the last three months, I can attest that
this incisionless technique offers our patients a tremendous
improvement in their quality of life. It allows them the
ability to eat foods and beverages they could not tolerate
before the procedure but, most importantly, it allows them
to discontinue their use of GERD medications in the majority
of cases, which is especially important for women in the
face of osteoporosis. With no skin incisions, no cutting of
vessels, and no dissection of the fundus, the EsophyX device
represents a new era in antireflux treatment and offers
patients an innovative, state-of-the-art surgical procedure
that will allow them to no longer live their lives
pill-to-pill."
Dr. Scott Melvin, Professor of Surgery, Director of the
Center for Minimally Invasive Surgery and Chief of the
Division of General & Gastrointestinal Surgery at The Ohio
State University (OSU) Medical Center, will be demonstrating
this new TIF technique at a live case course at OSU February
29th: "I am very impressed with the clinical results for
EsophyX, including the reduction/elimination of hiatal
hernia and reduction/elimination of esophagitis. These
multi-center study results confirm the 2 year outcomes seen
in the first EsophyX study. With over 750 Natural Orifice
Surgical cases performed to date, utilizing EndoGastric
Solutions technology platforms, it is clear that TIF is a
mainstream procedure that most advanced foregut surgeons
should be incorporating into their clinical practice. Any
surgeon considering being a natural orifice surgeon should
come see the techniques and learn more at our course."
"We are very pleased with the outstanding results of our
first two GERD clinical studies," states Thierry Thaure, CEO
of EndoGastric Solutions (EGS) Inc. "These results were
achieved with the first version of the EsophyX device and
TIF 1 procedure. We believe in continuous improvement and
are already teaching a much improved TIF 2 technique in our
training center in Redmond, Washington that has shown even
stronger outcomes. We are encouraged that surgeons and
advanced surgical endoscopists are rapidly adopting these
new incisionless procedures, as patients are demanding a
permanent solution for their reflux disease in the face of
failing pharmacological therapy."
About EndoGastric Solutions
EndoGastric Solutions (EGS) is a privately held corporation
located in Redmond, Washington and Redwood City, California.
EGS is a pioneer in developing incisionless transoral
procedures for the treatment of upper gastrointestinal
diseases, including gastroesophageal reflux disease (GERD)
and other GI conditions. EsophyX and StomaphyX(TM) are
cleared by the FDA for specific indications, are CE marked,
and are available for sale in the U.S. and Europe.
For more information about EndoGastric Solutions, Inc.,
EsophyX(TM) and StomaphyX(TM), please visit:
US: http://www.endogastricsolutions.com
EU: http://www.egseurope.eu
Other locations: http://www.egsglobal.net
For more information about the Ohio State University Medical
Center Leap into the Future with Advances in Transoral
Foregut Surgery course please visit:
http://www.cmis.ohio-state.edu
EndoGastric Solutions
EndoGastric soluþii (tm) anunta rezultatele EsophyX (tm) multi-Gerd Centrul de studiu - EndoGastric Solutions(TM) Announces Results Of EsophyX(TM) Multi-Center GERD Study - articole medicale engleza - startsanatate